Regular and Young Investigator Award Abstracts 2022
DOI: 10.1136/jitc-2022-sitc2022.0095
|View full text |Cite
|
Sign up to set email alerts
|

95 Characterization of human breast cancer tissue with the Xenium In Situ platform reveals a novel marker for invasiveness

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
3
2

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(3 citation statements)
references
References 2 publications
0
3
0
Order By: Relevance
“…Our approach could also extend to identify other spatially-resolved molecular features, such as protein interactions [52,53]. Validation of our findings using pathological examination of underlying cellular phenomena, through immunohistochemistry and other single-cell level spatial analysis platforms like Xenium/merScope is essential [54,55], as this study serves as a proof of concept. We anticipate applying our models to a larger cohort to identify metastasis and recurrence predictors at a population scale.…”
Section: Discussionmentioning
confidence: 89%
“…Our approach could also extend to identify other spatially-resolved molecular features, such as protein interactions [52,53]. Validation of our findings using pathological examination of underlying cellular phenomena, through immunohistochemistry and other single-cell level spatial analysis platforms like Xenium/merScope is essential [54,55], as this study serves as a proof of concept. We anticipate applying our models to a larger cohort to identify metastasis and recurrence predictors at a population scale.…”
Section: Discussionmentioning
confidence: 89%
“…For instance, the enhanced workflow does not yet apply to fresh frozen sections which will be the subject of future work. To affirm the universality and adaptability of the models, varied staining methodologies, slide preparations, and tissue specimens should be considered, requiring additional forms of validation (e.g., immunostaining, alternative spatial transcriptomic assays) [44][45][46]. Such disparities can introduce unpredicted variability, with potential ramifications on model efficiency.…”
Section: Discussionmentioning
confidence: 99%
“…Using Xenium, Henley et at. revealed that invasive fronts of ductal carcinoma in situ (DCIS) BC were characterized by disrupted myoepithelial layers, and low KRT14 expression which were also positive for progesterone receptor ( 37 ); Janesick et al. predicted the hormone receptor status of three BC subtypes (low-grade and high-grade DCIS, and invasive carcinoma) whose molecular signatures were also characterized using whole-transcriptomics Visium on adjacent tissue sections ( 38 ).…”
Section: St Techniquesmentioning
confidence: 99%